GlassScriptPhysician profile
Richard Lewis
NPI 1740220201
$309,420.90
in general payments reported to CMS, 2019-2025
26 companies · $56K in 2025
The $56K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $90K · 2021: $10K · 2022: $21K · 2023: $72K · 2024: $42K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $103K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Travel and Lodging: $21K · Food and Beverage: $1,817 · Education: $59.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $103,032.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,530.50 |
| Travel and Lodging | $20,606.07 |
| Food and Beverage | $1,817.34 |
| Education | $59.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $104,262.99 | 2019-2025 | Hizentra, Privigen |
| Argenx US, INC. | $66,010.43 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Sanofi US Services INC. | $33,412.04 | 2020-2023 | |
| Janssen Research & Development, LLC | $31,200.00 | 2025 | |
| Genzyme Corporation | $29,040.69 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $8,823.00 | 2020-2025 | |
| Janssen Global Services, LLC | $6,214.89 | 2023-2024 | |
| Akcea Therapeutics, INC. | $6,107.62 | 2019 | |
| Seagen INC. | $4,400.00 | 2019 | |
| Grifols Shared Services North America, INC. | $3,925.00 | 2021-2025 | |
| Ucb Sa | $3,300.00 | 2020 | |
| Alnylam Pharmaceuticals INC. | $2,763.18 | 2021-2022 | |
| Genentech, INC. | $2,640.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,750.00 | 2022 | |
| Janssen Biotech, INC. | $1,635.00 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,200.00 | 2025 | Uplizna |
| Octapharma USA, INC. | $1,024.20 | 2021-2022 | |
| Grifols USA, LLC | $1,000.00 | 2020 | |
| Alexion Pharmaceuticals, INC. | $326.37 | 2024-2025 | |
| Gilead Sciences, INC. | $147.88 | 2025 | |
| Novartis Pharmaceuticals Corporation | $113.99 | 2019 | |
| Astellas Pharma US INC | $85.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $25.60 | 2024 | |
| Life Molecular Imaging LTD | $13.02 | 2025 | Neuraceq |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.